HUM vs IOVA
Humana vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | HUM | IOVA |
|---|
| AI Score |
68
|
67
|
| Price |
$389.25
|
$6.99
|
| P/E Ratio |
36.53×
|
-9.97×
|
| ROE |
6.7%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
13.7%
|
116.3%
|
| Debt / Equity |
0.74×
|
0.06×
|
| Dividend Yield |
0.9%
|
0.0%
|
| RSI (14) |
58.2
|
78.6
|
| Beta |
0.74
|
0.701
|
| Expected Upside |
+9.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for HUM versus IOVA.
HUM leads by 1 points.
HUM scores 68/100 (Buy) versus IOVA at 67/100 (Buy).
HUM Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 78 -- overbought on the larger timeframe too — Technical